Molecular diagnostics

Point Of Care Diagnostics Market Worth $46.7 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Thursday, November 21, 2019 - 1:30pm

The glucose monitoring products segment is expected to account for the largest share of the POC Diagnostics Market in 2019.

Key Points: 
  • The glucose monitoring products segment is expected to account for the largest share of the POC Diagnostics Market in 2019.
  • Based on platform, the Point Of Care Diagnostics Market is segmented into lateral flow assays, immunoassays, molecular diagnostics, dipsticks, and microfluidics.
  • Based on end user, the Point Of Care Diagnostics Market is segmented into clinical laboratories and outpatient healthcare & ambulatory care settings, hospitals/critical care centers, home care settings, and other end users.
  • Get 10% Customization on this Research Report:
    The Point Of Care Diagnostics Market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Point Of Care Diagnostics Market Worth $46.7 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Thursday, November 21, 2019 - 1:30pm

The glucose monitoring products segment is expected to account for the largest share of the POC Diagnostics Market in 2019.

Key Points: 
  • The glucose monitoring products segment is expected to account for the largest share of the POC Diagnostics Market in 2019.
  • Based on platform, the Point Of Care Diagnostics Market is segmented into lateral flow assays, immunoassays, molecular diagnostics, dipsticks, and microfluidics.
  • Based on end user, the Point Of Care Diagnostics Market is segmented into clinical laboratories and outpatient healthcare & ambulatory care settings, hospitals/critical care centers, home care settings, and other end users.
  • Get 10% Customization on this Research Report:
    The Point Of Care Diagnostics Market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer

Thursday, November 21, 2019 - 1:05pm

With the launch of this new assay, Biocept now offers 20 CLIA-certified liquid biopsy tests utilizing its Target Selector platform to determine the status of actionable solid tumor biomarkers.

Key Points: 
  • With the launch of this new assay, Biocept now offers 20 CLIA-certified liquid biopsy tests utilizing its Target Selector platform to determine the status of actionable solid tumor biomarkers.
  • "Biocept's novel liquid biopsy testsare designed tohelp physiciansrapidly and in real-time identifykeybiomarkersof interest to facilitate the clinical decision making process."
  • Biocept's novel Target Selector pan-TRK assay is a liquid biopsy test designed to detect NTRK antibodies from a patient's blood sample.
  • The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer.

Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients

Tuesday, November 19, 2019 - 2:30pm

These include data from a study evaluating the clinical risk of recurrence among premenopausal women 50 years of age with breast cancer.

Key Points: 
  • These include data from a study evaluating the clinical risk of recurrence among premenopausal women 50 years of age with breast cancer.
  • Two additional presentations will feature the first datasets from Agendia's ongoing multicenter, prospective, observational trial for patients with Stage I, II, and III breast cancer (FLEX).
  • Agendia is a molecular diagnostics company committed to improving clinical outcomes and informing the journey for patients with early stage breast cancer.
  • By developing evidence-based, novel genomic tests, Agendia aims to support the evolving clinical needs of breast cancer patients and their physicians.

Global Molecular Diagnostics Market Size was Valued at 5,962 Million US$ in 2016 and is Expected to Reach 10,557 Million US$ with a CAGR of 9.1% by 2023 - Valuates Reports™

Monday, November 18, 2019 - 1:22pm

These methods are used to treat various infectious diseases

Key Points: 
  • These methods are used to treat various infectious diseases
    It is expected that technological advances in molecular diagnostics will drive the market dramatically as they allow for greater precision, portability and cost-effectiveness.
  • Because of the well-penetrated healthcare system and supportive regulatory policies, the European molecular diagnostics sector is the second-highest revenue generator.
  • The study provides an in-depth analysis of the global molecular diagnostics market and current trends and future estimations to elucidate the imminent investment pockets.
  • The global molecular diagnostics market is segmented by application into infectious diseases, oncology, genetic testing, blood screening, and others (microbiology, neurological diseases, and cardiovascular diseases).

Global Molecular Diagnostics Market Size was Valued at 5,962 Million US$ in 2016 and is Expected to Reach 10,557 Million US$ with a CAGR of 9.1% by 2023 - Valuates Reports™

Monday, November 18, 2019 - 1:05pm

These methods are used to treat various infectious diseases

Key Points: 
  • These methods are used to treat various infectious diseases
    It is expected that technological advances in molecular diagnostics will drive the market dramatically as they allow for greater precision, portability and cost-effectiveness.
  • Because of the well-penetrated healthcare system and supportive regulatory policies, the European molecular diagnostics sector is the second-highest revenue generator.
  • The study provides an in-depth analysis of the global molecular diagnostics market and current trends and future estimations to elucidate the imminent investment pockets.
  • The global molecular diagnostics market is segmented by application into infectious diseases, oncology, genetic testing, blood screening, and others (microbiology, neurological diseases, and cardiovascular diseases).

Global Clinical In Vitro Diagnostic Medical Laboratory Services Market to 2024: Genetic Based Testing Creates New Department and New Discipline

Thursday, November 14, 2019 - 5:15pm

3.2.2 Economic or population contraction.

Key Points: 
  • 3.2.2 Economic or population contraction.
  • 3.2.3 Testing usage analysis curtailing growth.
  • Laboratory Services Business of Oxford Immunotec
    Mars, Incorporated to Acquire VCA Inc.
    LabCorp & Interpace Extend Deal, Boost Cancer Portfolio
    8.
  • Country Markets - Latin America, Africa & The Middle East 2016 to 2024
    9.1.1 Clinical Chemistry - Volumes, Prices, Revenues
    9.1.4 Anatomic Pathology - Volumes, Prices, Revenues
    9.1.5 Molecular Diagnostics - Volumes, Prices, Revenues
    9.1.6 All Clinical Testing - Volumes, Prices, Revenues

OncoCyte Provides Corporate Update and Reports Third Quarter 2019 Financial Results

Thursday, November 14, 2019 - 9:05pm

ALAMEDA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the lung cancer care continuum, today reported financial and operating results for the third quarter ended September 30, 2019 and provided a corporate update.

Key Points: 
  • ALAMEDA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the lung cancer care continuum, today reported financial and operating results for the third quarter ended September 30, 2019 and provided a corporate update.
  • My first quarter at the helm of OncoCyte was marked with significant progress in establishing OncoCyte as a leader in early-stage lung cancer molecular diagnostics, said Ron Andrews, Chief Executive Officer of OncoCyte.
  • Cash used in operations was $4.9 million for this quarter as compared to approximately $2.5 million during the third quarter in 2018.
  • The Company will host a conference call today, November 14, 2019, at 4:30 pm EDT / 1:30 pm PDT to discuss the results along with recent corporate developments.

HTG Molecular Diagnostics Reports Third Quarter 2019 Results

Tuesday, November 12, 2019 - 9:01pm

Product and product-related services revenue increased by 228% and 125% in the three and nine-month periods, respectively, compared to the prior year periods

Key Points: 
  • Product and product-related services revenue increased by 228% and 125% in the three and nine-month periods, respectively, compared to the prior year periods
    TUCSON, Ariz., Nov. 12, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today reported its financial results for the third quarter ended September 30, 2019.
  • Hosted a Key Opinion Leader (KOL) Meeting in October 2019 highlighting the companys new Molecular Diagnostics offerings and the potential opportunity in breast cancer.
  • Net loss from operations for the third quarter of 2019 was $4.6 million, compared to $4.8 million for the third quarter of 2018 and $4.7 million for the second quarter of 2019.
  • Net loss per share was $(0.15) for the third quarter of 2019 compared to $(0.17) for the third quarter of 2018.

Takeaways from AMP 2019 in Baltimore: Users of Bionano’s Saphyr System Presented Results from Multiple Studies Demonstrating the System’s Utility for a Variety of Disease Indications

Tuesday, November 12, 2019 - 1:00pm

Focusing on molecular diagnostics, quality health care through excellence in clinical molecular testing is at the core of AMP.

Key Points: 
  • Focusing on molecular diagnostics, quality health care through excellence in clinical molecular testing is at the core of AMP.
  • The association organizes an annual meeting to further its vision of providing global expertise in molecular testing that drives patient care.
  • Saphyr users chose AMP as a venue to present updates to their findings using the Saphyr System for a variety of disease indications:
    Moffitt Cancer Center.
  • Ascites is the abnormal build-up of fluid in the abdomen, which can be caused by an inflammatory reaction to metastatic cancer cells.